Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-alpha are elevated in children with Langerhans cell histiocytosis
| Autor: | Mario Ripoli, Marta Zelazko, Diez Ra, Jorge Braier, Adriana Roy, Diego Rosso |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Pathology medicine.medical_specialty Adolescent medicine.medical_treatment Prednisolone Sialoglycoproteins Vinblastine Pathogenesis Langerhans cell histiocytosis Predictive Value of Tests Antineoplastic Combined Chemotherapy Protocols medicine Humans Child Histiocyte Etoposide Chemotherapy business.industry Tumor Necrosis Factor-alpha Interleukin Infant Receptors Interleukin-1 Hematology medicine.disease Recombinant Proteins Histiocytosis Langerhans-Cell Interleukin 1 Receptor Antagonist Protein Interleukin 1 receptor antagonist Cytokine Oncology Child Preschool Pediatrics Perinatology and Child Health Tumor necrosis factor alpha Female business |
| Zdroj: | Journal of pediatric hematology/oncology. 25(6) |
| ISSN: | 1077-4114 |
| Popis: | PURPOSE Langerhans cell histiocytosis (LCH) is a rare disease with variable prognosis in which lesions and clinical features suggest that pro- and anti-inflammatory cytokines may be involved in its pathogenesis. The authors wished to evaluate whether serum levels of interleukin-1 receptor agonist (IL-1Ra) and tumor necrosis factor-alpha (TNF-alpha) are elevated in children with LCH and decrease after chemotherapy. PATIENTS AND METHODS Circulating levels of IL-1Ra and TNF-alpha were measured in 23 and 8 children with LCH, respectively, and 7 pediatric controls using commercially available ELISA kits. All patients fulfilled the Histiocyte Society LCH Protocols criteria for diagnosis, stratification, and treatment. RESULTS Pretreatment concentrations of IL-1Ra and TNF-alpha were found to be significantly elevated in patients with LCH compared with controls. Among LCH substages, a significant difference in IL-1Ra values was observed between individuals with single-system single-site disease vs. multisystem disease with risk-organ dysfunction. In all eight patients evaluated, IL-1Ra levels decreased after 6 weeks of chemotherapy. Lower values of TNF were observed in three patients after treatment. A positive and significant correlation between IL-1Ra and TNF serum concentrations was found. CONCLUSIONS Patients with LCH have elevated levels of IL-1Ra and TNF, which decrease after chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|